LLM Job #14088 - score_story_relevance
Conversation
You are a financial news analyst. Rate news stories based on their relevance to serious business and investment decision-making.
Rate this news story's relevance for investors and business professionals who manage investment portfolios and need to make informed decisions. This is ONE news story covered by MULTIPLE news sources. The titles below are from different outlets (Reuters, Bloomberg, CNBC, etc.) all reporting on the SAME business event. Rate the overall story's relevance. Article Titles: 1. Vinay Prasad, FDA’s vaccine regulator, waves off criticism in closed-door remarks 2. ‘Never seen anything like this’: alarm at memo from top US vaccine official 3. FDA chief says Biden administration withheld data on heart risk from Covid vaccines 4. FDA links 10 children's deaths to COVID-19 vaccines. Doctors want proof 5. Former F.D.A. Commissioners Sound Alarm on Plan to Change Vaccine Policy 6. FDA to raise hurdles for vaccines, faulting COVID shots for 10 kids' deaths 7. Blaming some child deaths on covid shots, FDA vows stricter vaccine rules Scoring Guidelines: - 9-10: Critical business news (earnings reports, Fed decisions, major M&A, sector-wide impact, regulatory changes) - 7-8: Important analysis (market trends, analyst insights, significant company developments, economic indicators) - 5-6: Relevant news (notable company announcements, industry developments, financial performance) - 3-4: Minor business news (routine updates, small moves, tangential business stories) - 1-2: Fluff/entertainment (celebrity CEO drama, viral marketing, cultural controversies, consumer complaints) High-value examples: - "Wall Street Sentiment on AI Companies Shifts as Earnings Disappoint" (9-10) - "Federal Reserve Minutes Reveal Concerns About Inflation Persistence" (9-10) - "Apple Supplier Cuts Production by 20% Amid Weak iPhone Demand" (8-9) - "Banking Sector Faces Regulatory Scrutiny After Failed Stress Tests" (8-9) Low-value examples: - "Starbucks Cup Design Sparks Outrage on Social Media" (1-2) - "CEO's Dog Makes Appearance at Company Event" (1-2) - "Company Changes Office Snack Selection" (1-2)
{
"explanation": "This collection of headlines centers on a highly sensitive and controversial claim by the FDA—specifically, that it has linked 10 children's deaths to COVID-19 vaccines and plans to raise regulatory hurdles for future vaccines. While the individual headlines vary in tone and framing (some alarmist, some factual), they all report on a single major regulatory event with significant implications.\n\nThe story involves a top U.S. health regulator (Vinay Prasad) making public remarks about withheld data, internal memos, and a shift in policy that could impact vaccine development, approval timelines, and public trust. This has direct implications for:\n\n- Biopharmaceutical and vaccine manufacturers (e.g., Pfizer, Moderna, Johnson \u0026 Johnson) whose stock prices and R\u0026D pipelines could be affected.\n- Investors in healthcare, biotech, and life sciences sectors.\n- Regulatory risk assessments for future vaccine approvals and public health policy.\n- Market sentiment around pandemic-related medical products and government oversight.\n\nEven if the validity of the claim is under scrutiny, the *fact* that the FDA is considering tightening vaccine approval standards based on adverse event data—even if disputed—represents a material regulatory shift with wide-reaching business and investment implications.\n\nThe involvement of former FDA commissioners and internal controversy adds weight, suggesting potential policy instability or institutional conflict that investors must monitor.\n\nTherefore, despite the sensationalized headlines, the underlying event is a critical regulatory development with direct impact on healthcare policy, biopharma investment decisions, and risk management in public health sectors.\n\nThis is not a cultural or entertainment story. It involves government health authority actions with potential market-moving consequences.\n\nRating: 9-10 (Critical business news).",
"score": 9
}Debug Information
▶ Structured Output Schema (JSON Schema)
{
"json_schema": {
"description": "Business relevance score for a news story",
"name": "story_relevance",
"schema": {
"additionalProperties": false,
"properties": {
"explanation": {
"description": "1-2 sentence explanation of the score",
"type": "string"
},
"score": {
"description": "Relevance score (1-10)",
"maximum": 10,
"minimum": 1,
"type": "integer"
}
},
"required": [
"score",
"explanation"
],
"type": "object"
},
"strict": true
},
"type": "json_schema"
}▶ Token Usage & Performance
{
"completion_tokens": 373,
"predicted_ms": 0,
"prompt_ms": 0,
"prompt_tokens": 497,
"total_tokens": 870
}▶ Context & Parameters (Full JSON)
{
"article_count": 7,
"explanation": "This collection of headlines centers on a highly sensitive and controversial claim by the FDA—specifically, that it has linked 10 children's deaths to COVID-19 vaccines and plans to raise regulatory hurdles for future vaccines. While the individual headlines vary in tone and framing (some alarmist, some factual), they all report on a single major regulatory event with significant implications.\n\nThe story involves a top U.S. health regulator (Vinay Prasad) making public remarks about withheld data, internal memos, and a shift in policy that could impact vaccine development, approval timelines, and public trust. This has direct implications for:\n\n- Biopharmaceutical and vaccine manufacturers (e.g., Pfizer, Moderna, Johnson \u0026 Johnson) whose stock prices and R\u0026D pipelines could be affected.\n- Investors in healthcare, biotech, and life sciences sectors.\n- Regulatory risk assessments for future vaccine approvals and public health policy.\n- Market sentiment around pandemic-related medical products and government oversight.\n\nEven if the validity of the claim is under scrutiny, the *fact* that the FDA is considering tightening vaccine approval standards based on adverse event data—even if disputed—represents a material regulatory shift with wide-reaching business and investment implications.\n\nThe involvement of former FDA commissioners and internal controversy adds weight, suggesting potential policy instability or institutional conflict that investors must monitor.\n\nTherefore, despite the sensationalized headlines, the underlying event is a critical regulatory development with direct impact on healthcare policy, biopharma investment decisions, and risk management in public health sectors.\n\nThis is not a cultural or entertainment story. It involves government health authority actions with potential market-moving consequences.\n\nRating: 9-10 (Critical business news).",
"finish_reason": "stop",
"google_story_id": 13088,
"max_tokens": 2000,
"relevance_score": 9,
"response_format": "json_schema",
"response_format_details": {
"json_schema": {
"description": "Business relevance score for a news story",
"name": "story_relevance",
"schema": {
"additionalProperties": false,
"properties": {
"explanation": {
"description": "1-2 sentence explanation of the score",
"type": "string"
},
"score": {
"description": "Relevance score (1-10)",
"maximum": 10,
"minimum": 1,
"type": "integer"
}
},
"required": [
"score",
"explanation"
],
"type": "object"
},
"strict": true
},
"type": "json_schema"
},
"temperature": 0
}